Latest revenue
$26.5M
as of 2026-03-31
Latest net income
$-19.7M
as of 2026-03-31
Net margin
-74.5%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $712.2M
- Enterprise value
- $712.2M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $24.33
- 52-wk low
- $10.85
- Beta
- —
- Shares out
- 37.9M
5-year trend
What this company does
Item 1. Business. Overview We are a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. We are initially focused on becoming the standard of care for the detection and management of seizures in the…
AI summary unavailable — showing raw filing excerpt
Generated from CBLL's filing dated 2026-02-24
Key risks
Item 1A. Risk Factors. Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report, including our financial statements and the related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could have a material adverse effect on our business, financial condition, results of operations, and prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your…
AI summary unavailable — showing raw filing excerpt
Generated from CBLL's filing dated 2026-02-24
Profitability
Gross margin
87.9%
1.4%Operating margin
-65.6%
8.1%Net margin
-60.0%
3.0%Return on equity
-34.4%
62.5%Return on assets
-27.3%
52.0%Leverage
Debt / equity
0.26×
45.4%Long-term debt / equity
0.13×
24.7%Debt / assets
20.7%
36.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $26.5M | +29.3% | $-19.7M | -54.5% | -74.5% |
Q4 2025 2025-12-31 | $24.8M | +33.7% | $-13.5M | -7.6% | -54.6% |
Q3 2025 2025-09-30 | $22.6M | +31.4% | $-13.5M | -29.3% | -59.6% |
Q2 2025 2025-06-30 | $21.2M | +38.4% | $-13.6M | -52.6% | -64.4% |
Q1 2025 2025-03-31 | $20.5M | +42.3% | $-12.8M | -49.9% | -62.4% |
Q4 2024 2024-12-31 | $18.5M | — | $-12.6M | — | -67.9% |
Q3 2024 2024-09-30 | $17.2M | +48.1% | $-10.4M | -47.7% | -60.6% |
Q2 2024 2024-06-30 | $15.3M | — | $-8.9M | — | -58.4% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Electromedical & Electrotherapeutic Apparatus · SIC 3845
Your notes
Keep private notes on CBLL — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$14.0M
Net activity
−$14.0M
Distinct insiders
9
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns CBLL
Institutional value
$229.8M
Total shares held
12.5M
Distinct holders
63
-52 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | Red Tree Management, LLC | 2.2M | $40.4M | +0 (+0.0%) | No change |
| 2 | BlackRock, Inc. | 1.8M | $33.2M | -35.3K (-1.9%) | Trimmed |
| 3 | KCM Capital Inc | 1.4M | $25.7M | +400.0K (+40.0%) | Added |
| 4 | Bank of New York Mellon Corp | 1.2M | $21.3M | -61.2K (-5.0%) | Trimmed |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 1.1M | $20.8M | — | New |
| 6 | FEDERATED HERMES, INC. | 939.5K | $17.2M | +152.7K (+19.4%) | Added |
| 7 | FRANKLIN RESOURCES INC | 809.5K | $14.8M | +286.2K (+54.7%) | Added |
| 8 | TimesSquare Capital Management, LLC | 716.5K | $13.1M | -71.5K (-9.1%) | Trimmed |
| 9 | ROYCE & ASSOCIATES LP | 515.7K | $9.5M | -17.6K (-3.3%) | Trimmed |
| 10 | PEREGRINE CAPITAL MANAGEMENT LLC | 348.2K | $6.4M | -14.8K (-4.1%) | Trimmed |
| 11 | JPMORGAN CHASE & CO | 287.2K | $5.1M | -100.8K (-26.0%) | Trimmed |
| 12 | VANGUARD PORTFOLIO MANAGEMENT LLC | 214.2K | $3.9M | — | New |
| 13 | VANGUARD FIDUCIARY TRUST CO | 163.1K | $3.0M | — | New |
| 14 | BNP PARIBAS FINANCIAL MARKETS | 106.0K | $1.9M | -117.5K (-52.6%) | Trimmed |
| 15 | DEUTSCHE BANK AG\ | 88.5K | $1.6M | +3.3K (+3.9%) | Added |
| 16 | F/M Investments LLC | 88.4K | $1.6M | -3.8K (-4.1%) | Trimmed |
| 17 | EMERALD MUTUAL FUND ADVISERS TRUST | 88.4K | $1.6M | -3.8K (-4.1%) | Trimmed |
| 18 | Nuveen, LLC | 54.9K | $1.0M | +311 (+0.6%) | Added |
| 19 | SEI INVESTMENTS CO | 50.4K | $923.1K | +1.1K (+2.3%) | Added |
| 20 | JANE STREET GROUP, LLC | 43.0K | $787.7K | +8.2K (+23.5%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once CBLL's latest filing finishes processing.